BGDV - ETF AI Analysis
Top Page
Bahl & Gaynor Dividend ETF (BGDV)
BGDV, the Bahl & Gaynor Dividend ETF, appears to be a solid-quality fund, supported by strong core holdings like TSM and AVGO, which benefit from leading positions in advanced and AI-related technologies and robust financial performance. Additional contributors such as VCTR and APH add stability through attractive valuations, dividends, and strategic growth initiatives, while weaker names like ABBV and EHC, with leverage, liquidity, and profitability concerns, modestly weigh on the overall picture. The main risk factor is the fund’s meaningful exposure to high-valuation, growth-oriented companies, which could be more vulnerable if future growth or cash flow expectations are not met.
BGDV vs. SPDR S&P 500 ETF (SPY)
- AUM
- 868.36M
- Region
- North America
- Expense Ratio
- 0.45%
- Beta
- 0.75
- Issuer
- Bahl & Gaynor
- Inception Date
- Dec 11, 2024
- Dividend Yield
- 0.94%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
BGDV Summary
The Bahl & Gaynor Dividend ETF (BGDV) is a U.S. stock fund focused on dividend-paying companies across the whole market, rather than tracking a specific index. It owns businesses from many sectors, including technology, health care, and financials. Well-known holdings include Nvidia and Eli Lilly, along with other established firms that pay regular dividends. Someone might invest in BGDV to seek a mix of income from dividends and long-term growth, while staying diversified across many industries. A key risk is that stock prices and dividend payments can go up and down with the overall market.
How much will it cost me?
This ETF has an expense ratio of 0.45%, which means you’ll pay about $4.50 per year for every $1,000 invested. That’s higher than the average low-cost index ETF because BGDV is actively managed, with professionals selecting dividend-focused stocks rather than simply tracking a market index.
What would affect this ETF?
BGDV could benefit if U.S. economic growth stays solid, technology and health care companies continue to innovate, and demand for reliable dividend income remains strong, supporting its large positions in firms like Nvidia, Eli Lilly, and AbbVie. On the other hand, higher interest rates, market downturns that hurt dividend-paying stocks, or sector-specific challenges in technology, financials, or health care could weigh on the fund’s performance, especially given its focus on U.S. companies.
BGDV Top 10 Holdings
BGDV leans heavily on a mix of U.S. dividend payers with a tech and health-care tilt, and a few standout financial and energy names doing the heavy lifting. Victory Capital and Targa Resources have been rising steadily, giving the fund a strong tailwind, while Eli Lilly, AbbVie, and Encompass Health add steady, health-care-driven support. On the tech side, Nvidia and Broadcom have seen more mixed, sometimes lagging action lately, so they’re no longer the sole engines of growth. Overall, it’s a U.S.-centric, dividend-focused portfolio with balanced sector exposure.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 TSM | TSMC | 4.91% | $43.83M | $1.92T | 33.94% | 81Outperform |
 LLY | Eli Lilly & Co | 3.97% | $35.44M | $1.29T | 67.86% | 72Outperform |
 VCTR | Victory Capital Holdings | 3.83% | $34.15M | $7.05B | 78.77% | 80Outperform |
 ABBV | AbbVie | 3.47% | $30.94M | $513.86B | 29.22% | 66Neutral |
 MSI | Motorola Solutions | 3.37% | $30.09M | $81.44B | 13.79% | 70Neutral |
 NVDA | Nvidia | 3.23% | $28.84M | $5.15T | 0.86% | 76Outperform |
 AVGO | Broadcom | 3.27% | $29.18M | $1.65T | -13.38% | 76Outperform |
 UNH | UnitedHealth | 3.01% | $26.84M | $368.83B | 18.05% | 72Outperform |
 EHC | Encompass Health | 3.00% | $26.75M | $12.97B | 16.34% | 64Neutral |
 TRGP | Targa Resources | 2.83% | $25.25M | $66.98B | 107.89% | 74Outperform |
BGDV Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BGDV, the sentiment is Positive. The current price of 31.27 is above the 20-day moving average (MA) of 30.99, above the 50-day MA of 30.78, and above the 200-day MA of 29.87, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 58.63 is Neutral, neither overbought nor oversold. The STOCH value of 81.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BGDV.
BGDV Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| BGDV | $31.27 | $35.00(11.93% Upside) | $868.36M | 0.45% | 74Outperform |
 SEUS | $25.65 | $31.38(22.33% Upside) | $945.28M | 0.30% | 73Outperform |
 AAUB | $49.94 | $62.07(24.29% Upside) | $850.07M | 0.10% | 66Neutral |
 AVTM | $53.85 | $65.72(22.04% Upside) | $780.66M | 0.22% | 60Neutral |
 XCHG | $27.13 | $33.96(25.19% Upside) | $718.05M | 0.50% | 70Neutral |
 SMRI | $47.20 | $56.57(19.85% Upside) | $701.92M | 0.71% | 73Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BGDV | Bahl & Gaynor Dividend ETF | 31.27 | 5.03 | 19.16% | |
| SEUS | SEI QiM U.S. Equity Factor Allocation Active ETF | 25.65 | 0.39 | 1.53% | |
| AAUB | Alpha Architect US Equity 4 ETF | 49.94 | 0.45 | 0.91% | |
| AVTM | Avantis Total Equity Markets ETF | 53.85 | 4.21 | 8.47% | |
| XCHG | AB US Equity ETF | 27.13 | 2.28 | 9.18% | |
| SMRI | Bushido Capital US Equity ETF | 47.20 | 12.86 | 37.44% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.